When was Avidity Biosciences founded?

Avidity Biosciences was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Avidity Biosciences located?

Avidity Biosciences is headquartered in San Diego, United States.

How many employees does Avidity Biosciences have?

As of Mar 31, 2026, the latest employee count at Avidity Biosciences is 484.

Is Avidity Biosciences a funded company?

Avidity Biosciences is a funded company, having raised a total of $143M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 14, 2014.

How much is Avidity Biosciences worth?

The last known valuation of Avidity Biosciences was $***** as of Jun 11, 2020.

When was the latest funding round of Avidity Biosciences?

Avidity Biosciences' latest funding was a $***** Post IPO round on Mar 04, 2024, with participation from 0 investor.

What is the annual revenue of Avidity Biosciences?

Annual revenue of Avidity Biosciences is $18.8M as on Dec 31, 2025.

Where does Avidity Biosciences rank among its competitors?

Avidity Biosciences ranks 3rd amongst 2031 active competitors, of which 500 are funded. It stands 9th in terms of total funding among its competitors.

Who are the top competitors of Avidity Biosciences?

Avidity Biosciences' top competitors include Alnylam, Sutro Biopharma and Synthego. Among them, Avidity Biosciences secured the most recent funding round in March, 2024.

Avidity Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

RNA therapeutics innovator targeting muscle and other diseases with AOC platform. The company is dedicated to improving lives through targeted RNA therapeutics, utilizing its Antibody Oligonucleotide Conjugates (AOC™) platform. The focus is on addressing the root causes of diseases, particularly in muscle disease. The innovative pipeline is designed to expand into various cells and tissues, addressing unmet patient needs across a wide range of therapeutic areas. The AOC platform combines the specificity of monoclonal antibodies with the precision of oligonucleotides to deliver treatments to previously inaccessible tissues and cells, effectively targeting the underlying genetic drivers of diseases. The company is advancing pipeline programs to offer treatment options for patients and their families. The company is a biotechnology company focused on research and development.

Email ID: *****@aviditybio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

San Diego, United States

Stage

Acquired

Total Funding

$143M in 7 rounds

Latest Funding Round

Post IPO, Mar 04, 2024, $*****

Last Known Valuation

$***** as on Jun 11, 2020

Investors

Lilly & 20 more

Ranked

3^rd among 2031 active competitors

Annual Revenue

$18.8M as on Dec 31, 2025

Employee Count

484 as on Mar 31, 2026

Similar Companies

Alnylam & 2758 more

Exit Details

Acquired by Novartis (Oct 27, 2025)

View Avidity Biosciences' full profile

Avidity Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVIDITY BIOSCIENCES LLC CIN: 401-7900 , Belgium, Active	Nov 12, 2012	-	253 (As on Feb 29, 2024)	-
Avidity Biosciences, Inc. CIN: 1599901 , United States, Active	Nov 12, 2012	$18.8M (As on Dec 31, 2025)	-	-

Avidity Biosciences got acquired by Novartis on Oct 27, 2025 at an acquisition amount of $12B. It was facilitated by Homburger.

Click here to take a look at Avidity Biosciences's acquisition in detail

Avidity Biosciences has raised a total funding of $143M over 7 rounds. Its first funding round was on Feb 14, 2014. Avidity Biosciences has 21 institutional investors.

Here is the list of recent funding rounds of Avidity Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2024	4423494	Post IPO	5078235	4758517	1166052	1516393
Nov 13, 2019	8631196	Series C	9973785	9410463	5600692	ST PHARM & 11 more
Apr 22, 2019	5626255	Series B	7818379	7888358	Lilly	6964122

Access funding benchmarks and valuations. Sign up today!

View details of Avidity Biosciences's funding rounds and investors

The founders of Avidity Biosciences are Troy Wilson and Kent Hawryluk.

Here are the details of Avidity Biosciences' key team members:

Troy Wilson: Co-Founder & CEO of Avidity Biosciences and founder of 2 other companies, Wellspring Biosciences and Avidity Biosciences.
Kent Hawryluk: Co-Founder of Avidity Biosciences and founder of 1 other company.

View details of Avidity Biosciences's Founder profiles and Board Members

Avidity Biosciences' employee count trend

Avidity Biosciences has 484 employees as of Mar 26. Here is Avidity Biosciences's employee count trend over the years:

Employee count trend for Avidity Biosciences

Uncover Avidity Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avidity Biosciences include Alnylam, Sutro Biopharma and Synthego. Here is the list of Top 10 competitors of Avidity Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Military Health, GUB & 13 others	71/100
2nd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	71/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	EcoR1, PFM Health Sciences & 19 others	70/100
3rd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	69/100
5th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$152M	Viking Global Investors, Global Health Investment ... & 14 others	68/100
6th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Developing novel drugs based on a proteome-wide ligand and target discovery platform	$271M	Logos, Boxer Capital & 20 others	67/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA-editing technologies for precision medicine	$4M	Fidelity Investments, Citadel & 13 others	67/100
8th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Central Texas Angel Network ... & 19 others	67/100
9th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	66/100
10th	Silence Therapeutics 1999, London (United Kingdom), Public	Developer of RNA therapeutics for hematology and cardiovascular diseases	-	Mallinckrodt Pharmaceuticals, Adage Capital Management ... & 8 others	66/100